Uncontrolled, Open-Label Pre-Dinner Administration of Elobixibat in Japanese Adults with Chronic Constipation: A Retrospective Chart Review

BACKGROUND: Elobixibat has been approved as a new therapeutic drug for chronic constipation. Only the pharmacological efficacy and safety profile of pre-breakfast administration of elobixibat had been previously demonstrated. OBJECTIVE: We evaluated the efficacy and safety profile of pre-dinner admi...

Descripción completa

Detalles Bibliográficos
Autores principales: Odaka, Takeo, Tominaga, Kazunari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723766/
https://www.ncbi.nlm.nih.gov/pubmed/33320111
http://dx.doi.org/10.1016/j.curtheres.2020.100616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723766/
https://www.ncbi.nlm.nih.gov/pubmed/33320111
http://dx.doi.org/10.1016/j.curtheres.2020.100616

Ejemplares similares